Symbols / OSUR Stock $2.97 -1.66% OraSure Technologies, Inc.

Healthcare • Medical Instruments & Supplies • United States • NMS
OSUR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Instruments & Supplies
CEO Ms. Carrie Eglinton Manner
Exch · Country NMS · United States
Market Cap 204.48M
Enterprise Value 29.97M
Income -75.07M
Sales 113.02M
FCF (ttm) -6.88M
Book/sh 4.84
Cash/sh 2.54
Employees 500
Insider 10d —
IPO Nov 17, 1986
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.90
PEG 6.19
P/S 1.81
P/B 0.61
P/C —
EV/EBITDA -0.48
EV/Sales 0.27
Quick Ratio 4.58
Current Ratio 5.46
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.05
EPS next Y -0.50
EPS Growth —
Revenue Growth -6.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-06
ROA -10.84%
ROE -21.16%
ROIC —
Gross Margin 42.21%
Oper. Margin -82.99%
Profit Margin -66.42%
Shs Outstand 68.85M
Shs Float 62.13M
Insider Own 6.04%
Instit Own 88.89%
Short Float 4.60%
Short Ratio 8.72
Short Interest 3.01M
52W High 3.82
vs 52W High -22.25%
52W Low 2.08
vs 52W Low 42.79%
Beta 0.89
Impl. Vol. 25.00%
Rel Volume 1.68
Avg Volume 495.10K
Volume 832.33K
Target (mean) $4.75
Tgt Median $4.75
Tgt Low $3.50
Tgt High $6.00
# Analysts 2
Recom Buy
Prev Close $3.02
Price $2.97
Change -1.66%
About

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.75
Mean price target
2. Current target
$2.97
Latest analyst target
3. DCF / Fair value
$-1.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.97
Low
$3.50
High
$6.00
Mean
$4.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-12 main Stephens & Co. Equal-Weight → Equal-Weight $3
2025-05-19 main Evercore ISI Group In-Line → In-Line $3
2025-05-08 main Evercore ISI Group In-Line → In-Line $3
2024-08-07 main Evercore ISI Group In-Line → In-Line $5
2024-07-02 main Evercore ISI Group In-Line → In-Line $5
2024-05-13 main JP Morgan Neutral → Neutral $6
2024-04-04 main Evercore ISI Group In-Line → In-Line $7
2024-02-29 main JP Morgan Neutral → Neutral $7
2023-12-11 main Citigroup Buy → Buy $9
2023-11-08 main JP Morgan Neutral → Neutral $5
2023-07-17 main Stephens & Co. Equal-Weight → Equal-Weight $5
2022-05-11 main Citigroup — → Buy $10
2022-02-24 main Citigroup — → Buy $12
2021-09-22 down Raymond James Outperform → Market Perform —
2021-08-04 main Raymond James — → Outperform $13
2021-06-28 main Raymond James — → Outperform $11
2021-05-06 main Raymond James — → Outperform $12
2020-08-21 init Evercore ISI Group — → Outperform $22
2020-08-10 init JP Morgan — → Neutral $18
2020-08-10 init Citigroup — → Buy $18
News
RSS: Latest OSUR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-26 BOYD STEVEN KYLE Director — 5,246 $3.10 $16,249
2026-03-20 EGLINTON MANNER CARRIE Chief Executive Officer — 32,300 $2.93 $94,597
2026-03-20 MCGRATH KENNETH J Chief Financial Officer — 32,300 $2.93 $94,600
2026-03-13 EGLINTON MANNER CARRIE Chief Executive Officer — 22,022 $3.00 $66,033
2026-03-13 MCGRATH KENNETH J Chief Financial Officer — 22,021 $3.00 $66,030
2026-03-02 EGLINTON MANNER CARRIE Chief Executive Officer — 484,496 $0.00 $0
2026-03-02 ANTHONY MICHELE MARIE Officer — 57,165 $0.00 $0
2026-03-02 MCGRATH KENNETH J Chief Financial Officer — 115,162 $0.00 $0
2025-12-17 KENNY JOHN P Director — 10,286 $2.46 $25,304
2025-11-28 GAGLIANO NANCY J Director — 2,100 $2.37 $4,982
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
115.02
-38.10%
185.83
-54.17%
405.47
+4.64%
387.48
Operating Revenue
109.06
-40.93%
184.61
-54.10%
402.22
+6.39%
378.05
Cost Of Revenue
66.82
-37.22%
106.44
-54.48%
233.82
-2.18%
239.04
Reconciled Cost Of Revenue
66.82
-37.22%
106.44
-54.48%
233.82
-2.18%
239.04
Gross Profit
48.20
-39.29%
79.39
-53.75%
171.65
+15.64%
148.44
Operating Expense
116.32
+12.66%
103.25
-19.49%
128.24
-16.56%
153.68
Research And Development
42.53
+63.27%
26.05
-22.77%
33.73
-6.92%
36.24
Selling General And Administration
73.79
-4.41%
77.20
-18.31%
94.51
-19.53%
117.44
Selling And Marketing Expense
26.12
-15.71%
30.99
-14.68%
36.32
-26.24%
49.24
General And Administrative Expense
47.68
+3.16%
46.22
-20.58%
58.19
-14.68%
68.21
Other Gand A
47.68
+3.16%
46.22
-20.58%
58.19
-14.68%
68.21
Total Expenses
183.15
-12.66%
209.69
-42.09%
362.06
-7.81%
392.72
Operating Income
-68.12
-185.54%
-23.86
-154.95%
43.41
+928.04%
-5.24
Total Operating Income As Reported
-71.97
-154.76%
-28.25
-186.43%
32.68
+247.52%
-22.16
EBITDA
-58.15
-329.18%
-13.55
-121.06%
64.35
+525.21%
10.29
Normalized EBITDA
-54.31
-493.02%
-9.16
-112.20%
75.08
+175.98%
27.21
Reconciled Depreciation
9.97
-3.28%
10.31
-50.77%
20.94
+34.78%
15.54
EBIT
-68.12
-185.54%
-23.86
-154.95%
43.41
+928.04%
-5.24
Total Unusual Items
-3.85
+12.45%
-4.39
+59.07%
-10.73
+36.56%
-16.91
Total Unusual Items Excluding Goodwill
-3.85
+12.45%
-4.39
+59.07%
-10.73
+36.56%
-16.91
Special Income Charges
-3.85
+12.45%
-4.39
+59.07%
-10.73
+36.56%
-16.91
Impairment Of Capital Assets
0.00
-100.00%
4.39
-59.44%
10.83
-36.68%
17.10
Restructuring And Mergern Acquisition
4.57
0.00
+100.00%
-0.10
+47.34%
-0.19
Net Income
-68.73
-252.47%
-19.50
-136.34%
53.66
+413.17%
-17.13
Pretax Income
-64.59
-303.64%
-16.00
-128.44%
56.26
+458.90%
-15.68
Other Income Expense
3.54
-54.97%
7.86
-38.83%
12.84
+223.12%
-10.43
Other Non Operating Income Expenses
7.38
-39.73%
12.25
-48.04%
23.57
+263.74%
6.48
Gain On Sale Of Business
—
—
—
—
Tax Provision
1.80
+0.11%
1.80
-30.89%
2.60
+78.53%
1.46
Tax Rate For Calcs
0.00
+0.00%
0.00
+356.52%
0.00
-78.10%
0.00
Tax Effect Of Unusual Items
-0.81
+12.45%
-0.92
-86.86%
-0.49
+86.10%
-3.55
Net Income Including Noncontrolling Interests
-68.73
-252.47%
-19.50
-136.34%
53.66
+413.17%
-17.13
Net Income From Continuing Operation Net Minority Interest
-68.73
-252.47%
-19.50
-136.34%
53.66
+413.17%
-17.13
Net Income From Continuing And Discontinued Operation
-68.73
-252.47%
-19.50
-136.34%
53.66
+413.17%
-17.13
Net Income Continuous Operations
-68.73
-252.47%
-19.50
-136.34%
53.66
+413.17%
-17.13
Normalized Income
-65.69
-309.81%
-16.03
-125.09%
63.89
+1793.96%
-3.77
Net Income Common Stockholders
-68.73
-252.47%
-19.50
-136.34%
53.66
+413.17%
-17.13
Diluted EPS
-0.94
-261.54%
-0.26
-136.11%
0.72
+388.00%
-0.25
Basic EPS
-0.94
-261.54%
-0.26
-135.62%
0.73
+392.00%
-0.25
Basic Average Shares
73.48
-1.27%
74.43
+1.48%
73.35
+1.16%
72.50
Diluted Average Shares
73.48
-1.27%
74.43
+0.06%
74.39
+2.60%
72.50
Diluted NI Availto Com Stockholders
-68.73
-252.47%
-19.50
-136.34%
53.66
+413.17%
-17.13
Earnings From Equity Interest Net Of Tax
-2.34
-37.88%
-1.70
0.00
0.00
Gain On Sale Of PPE
0.72
0.00
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
403.17
-15.95%
479.66
-0.66%
482.85
+8.70%
444.18
Current Assets
261.91
-21.40%
333.22
-13.78%
386.46
+18.84%
325.19
Cash Cash Equivalents And Short Term Investments
199.28
-25.58%
267.76
-7.80%
290.41
+161.99%
110.85
Cash And Cash Equivalents
199.28
-25.58%
267.76
-7.80%
290.41
+245.80%
83.98
Other Short Term Investments
—
—
0.00
-100.00%
26.87
Receivables
22.20
-6.77%
23.82
-40.71%
40.17
-43.26%
70.80
Accounts Receivable
22.20
-6.77%
23.82
-40.71%
40.17
-43.26%
70.80
Gross Accounts Receivable
22.39
-8.94%
24.59
-40.59%
41.39
-43.43%
73.16
Allowance For Doubtful Accounts Receivable
-0.19
+75.71%
-0.77
+36.35%
-1.22
+48.58%
-2.37
Inventory
31.06
-9.17%
34.20
-28.18%
47.61
-50.25%
95.70
Raw Materials
14.83
-12.77%
17.00
-17.97%
20.73
-51.17%
42.45
Work In Process
2.02
-38.94%
3.31
+74.21%
1.90
-18.63%
2.33
Finished Goods
14.21
+2.33%
13.88
-44.43%
24.99
-50.93%
50.92
Prepaid Assets
5.22
+31.98%
3.96
-34.51%
6.04
-3.70%
6.27
Other Current Assets
4.15
+18.86%
3.49
+56.69%
2.23
-94.65%
41.57
Total Non Current Assets
141.26
-3.54%
146.44
+51.93%
96.39
-19.00%
118.99
Net PPE
51.32
-12.56%
58.69
+0.73%
58.27
-18.06%
71.11
Gross PPE
114.20
-8.36%
124.61
-13.11%
143.41
+1.72%
140.99
Accumulated Depreciation
-62.88
+4.61%
-65.92
+22.58%
-85.14
-21.84%
-69.88
Properties
0.00
0.00
0.00
0.00
Land And Improvements
1.12
+0.00%
1.12
+0.00%
1.12
+0.00%
1.12
Buildings And Improvements
39.07
+8.07%
36.15
+4.47%
34.61
-2.74%
35.58
Machinery Furniture Equipment
58.94
-8.11%
64.14
-25.11%
85.64
+5.12%
81.47
Construction In Progress
2.93
-69.52%
9.62
+4.56%
9.20
-17.33%
11.12
Other Properties
12.14
-10.64%
13.59
+5.77%
12.85
+9.87%
11.69
Goodwill And Other Intangible Assets
62.41
+8.04%
57.77
+56.54%
36.90
-21.15%
46.80
Goodwill
43.36
+7.52%
40.33
+12.98%
35.70
+1.69%
35.10
Other Intangible Assets
19.05
+9.24%
17.43
+1345.69%
1.21
-89.69%
11.69
Investments And Advances
25.96
-8.28%
28.30
0.00
0.00
Long Term Equity Investment
25.96
-8.28%
28.30
0.00
—
Non Current Deferred Assets
0.27
+73.72%
0.16
0.00
—
Non Current Deferred Taxes Assets
0.27
+73.72%
0.16
0.00
—
Other Non Current Assets
1.30
-14.61%
1.53
+25.29%
1.22
+12.05%
1.09
Total Liabilities Net Minority Interest
62.34
-10.07%
69.32
+32.87%
52.17
-34.58%
79.75
Current Liabilities
39.80
+18.85%
33.48
-15.31%
39.54
-42.75%
69.06
Payables And Accrued Expenses
14.87
-35.72%
23.13
-27.45%
31.88
-45.35%
58.33
Payables
7.67
-19.33%
9.51
-33.93%
14.40
-63.59%
39.54
Accounts Payable
6.52
-20.21%
8.17
-37.85%
13.15
-65.41%
38.02
Current Accrued Expenses
7.19
-47.17%
13.62
-22.11%
17.48
-6.96%
18.79
Total Tax Payable
1.15
-13.97%
1.34
+7.55%
1.25
-18.04%
1.52
Current Debt And Capital Lease Obligation
2.23
+2.63%
2.17
+2.55%
2.12
-28.10%
2.94
Current Capital Lease Obligation
2.23
+2.63%
2.17
+2.55%
2.12
-28.10%
2.94
Current Deferred Liabilities
1.52
-48.73%
2.96
+89.93%
1.56
-31.41%
2.27
Current Deferred Revenue
1.52
-48.73%
2.96
+89.93%
1.56
-31.41%
2.27
Other Current Liabilities
21.18
+305.51%
5.22
+31.12%
3.98
-27.83%
5.52
Total Non Current Liabilities Net Minority Interest
22.55
-37.09%
35.84
+183.57%
12.64
+18.20%
10.69
Long Term Debt And Capital Lease Obligation
10.97
-11.77%
12.43
+9.19%
11.39
+18.58%
9.60
Long Term Capital Lease Obligation
10.97
-11.77%
12.43
+9.19%
11.39
+18.58%
9.60
Non Current Deferred Liabilities
—
0.00
-100.00%
0.55
+35.78%
0.41
Non Current Deferred Taxes Liabilities
—
0.00
-100.00%
0.55
+35.78%
0.41
Other Non Current Liabilities
11.58
-50.54%
23.40
+3262.64%
0.70
+2.35%
0.68
Stockholders Equity
340.83
-16.94%
410.34
-4.72%
430.67
+18.18%
364.43
Common Stock Equity
340.83
-16.94%
410.34
-4.72%
430.67
+18.18%
364.43
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
70.39
-5.64%
74.60
+1.46%
73.53
+1.09%
72.73
Ordinary Shares Number
70.39
-5.64%
74.60
+1.46%
73.53
+1.09%
72.73
Additional Paid In Capital
531.39
-1.25%
538.13
+1.62%
529.54
+1.75%
520.45
Retained Earnings
-172.16
-66.45%
-103.43
-23.23%
-83.93
+39.00%
-137.59
Gains Losses Not Affecting Retained Earnings
-18.40
+24.45%
-24.36
-63.04%
-14.94
+18.95%
-18.43
Other Equity Adjustments
-18.40
+24.45%
-24.36
-63.04%
-14.94
+18.95%
-18.43
Total Equity Gross Minority Interest
340.83
-16.94%
410.34
-4.72%
430.67
+18.18%
364.43
Total Capitalization
340.83
-16.94%
410.34
-4.72%
430.67
+18.18%
364.43
Working Capital
222.11
-25.90%
299.74
-13.60%
346.92
+35.45%
256.13
Invested Capital
340.83
-16.94%
410.34
-4.72%
430.67
+18.18%
364.43
Total Debt
13.20
-9.63%
14.60
+8.15%
13.50
+7.63%
12.55
Capital Lease Obligations
13.20
-9.63%
14.60
+8.15%
13.50
+7.63%
12.55
Net Tangible Assets
278.42
-21.03%
352.57
-10.46%
393.77
+23.97%
317.63
Tangible Book Value
278.42
-21.03%
352.57
-10.46%
393.77
+23.97%
317.63
Other Inventories
—
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-49.02
-279.09%
27.37
-80.67%
141.58
+399.95%
-47.20
Cash Flow From Continuing Operating Activities
-49.02
-279.09%
27.37
-80.67%
141.58
+399.95%
-47.20
Net Income From Continuing Operations
-68.73
-252.47%
-19.50
-136.34%
53.66
+413.17%
-17.13
Depreciation Amortization Depletion
9.97
-3.28%
10.31
-50.77%
20.94
+34.78%
15.54
Depreciation
10.19
-6.25%
10.87
-48.07%
20.94
+36.77%
15.31
Amortization Cash Flow
-0.22
+60.64%
-0.56
-18900.00%
0.00
-98.68%
0.23
Depreciation And Amortization
9.97
-3.28%
10.31
-50.77%
20.94
+34.78%
15.54
Amortization Of Intangibles
-0.22
+60.64%
-0.56
-18900.00%
0.00
-98.68%
0.23
Other Non Cash Items
4.58
+20709.09%
0.02
+132.84%
-0.07
+28.72%
-0.09
Stock Based Compensation
10.15
-14.87%
11.92
+11.10%
10.73
-7.68%
11.62
Provisionand Write Offof Assets
-0.07
-191.55%
0.07
+115.37%
-0.46
+55.23%
-1.03
Asset Impairment Charge
0.00
-100.00%
4.39
-59.44%
10.83
-36.68%
17.10
Deferred Tax
1.85
+382.04%
-0.66
-744.12%
0.10
+106.18%
-1.65
Deferred Income Tax
1.85
+382.04%
-0.66
-744.12%
0.10
+106.18%
-1.65
Operating Gains Losses
1.98
-0.80%
2.00
+1841.75%
0.10
-81.87%
0.57
Net Foreign Currency Exchange Gain Loss
0.36
+238.78%
-0.26
-355.34%
0.10
+163.98%
-0.16
Gain Loss On Sale Of PPE
-0.72
-228.77%
0.56
0.00
-100.00%
0.73
Change In Working Capital
-8.76
-146.55%
18.82
-58.87%
45.76
+163.44%
-72.12
Change In Receivables
1.95
-87.72%
15.87
-48.99%
31.12
+223.66%
-25.16
Changes In Account Receivables
1.95
-87.72%
15.87
-48.99%
31.12
+223.66%
-25.16
Change In Inventory
3.56
-72.80%
13.10
-72.85%
48.23
+211.45%
-43.27
Change In Prepaid Assets
-2.37
-157.91%
4.09
+263.63%
-2.50
+64.76%
-7.09
Change In Payables And Accrued Expense
-10.38
+25.94%
-14.02
+53.82%
-30.36
-858.24%
4.00
Change In Accrued Expense
-8.66
-34.46%
-6.44
-90.40%
-3.38
-347.01%
1.37
Change In Payable
-1.72
+77.30%
-7.58
+71.91%
-26.98
-1124.15%
2.63
Change In Account Payable
-1.72
+77.30%
-7.58
+71.91%
-26.98
-1124.15%
2.63
Change In Other Working Capital
-1.52
-593.61%
-0.22
+70.00%
-0.73
-22.48%
-0.60
Investing Cash Flow
-6.81
+82.55%
-39.03
-158.99%
66.15
+213.75%
21.09
Cash Flow From Continuing Investing Activities
-6.81
+82.55%
-39.03
-158.99%
66.15
+213.75%
21.09
Net PPE Purchase And Sale
-4.20
-10.53%
-3.80
+63.15%
-10.30
+83.88%
-63.91
Purchase Of PPE
-4.20
-10.53%
-3.80
+63.15%
-10.30
+83.88%
-63.91
Capital Expenditure
-4.20
-10.53%
-3.80
+63.15%
-10.30
+83.88%
-63.91
Net Investment Purchase And Sale
0.00
+100.00%
-0.19
-100.69%
27.79
+13.23%
24.54
Purchase Of Investment
0.00
+100.00%
-53.24
+28.68%
-74.65
-226.38%
-22.87
Sale Of Investment
0.00
-100.00%
53.05
-48.21%
102.44
+116.05%
47.41
Net Business Purchase And Sale
-3.61
+89.69%
-35.04
0.00
0.00
Purchase Of Business
-3.61
+89.69%
-35.04
0.00
0.00
Gain Loss On Sale Of Business
—
—
—
0.00
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Net Other Investing Changes
1.00
—
48.67
-19.49%
60.45
Financing Cash Flow
-16.94
-305.75%
-4.18
-38.14%
-3.02
+21.03%
-3.83
Cash Flow From Continuing Financing Activities
-16.94
-305.75%
-4.18
-38.14%
-3.02
+21.03%
-3.83
Net Issuance Payments Of Debt
-0.06
+92.76%
-0.84
+37.40%
-1.34
+2.61%
-1.38
Repayment Of Debt
-0.06
+92.76%
-0.84
+37.40%
-1.34
+2.61%
-1.38
Long Term Debt Payments
-0.06
+92.76%
-0.84
+37.40%
-1.34
+2.61%
-1.38
Net Long Term Debt Issuance
-0.06
+92.76%
-0.84
+37.40%
-1.34
+2.61%
-1.38
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
-16.88
-375.85%
-3.55
-86.64%
-1.90
+15.66%
-2.25
Common Stock Payments
-16.88
-375.85%
-3.55
-86.64%
-1.90
+15.66%
-2.25
Repurchase Of Capital Stock
-16.88
-375.85%
-3.55
-86.64%
-1.90
+15.66%
-2.25
Proceeds From Stock Option Exercised
0.00
-100.00%
0.21
-20.45%
0.27
+1693.33%
0.01
Net Other Financing Charges
—
—
-0.05
+77.88%
-0.21
Changes In Cash
-72.78
-359.80%
-15.83
-107.73%
204.71
+783.63%
-29.95
Effect Of Exchange Rate Changes
4.29
+162.97%
-6.82
-497.90%
1.71
+160.38%
-2.84
Beginning Cash Position
267.76
-7.80%
290.41
+245.80%
83.98
-28.08%
116.76
End Cash Position
199.28
-25.58%
267.76
-7.80%
290.41
+245.80%
83.98
Free Cash Flow
-53.22
-325.73%
23.58
-82.04%
131.28
+218.15%
-111.11
Common Stock Issuance
—
—
—
0.00
Earnings Losses From Equity Investments
2.34
+37.88%
1.70
0.00
0.00
Issuance Of Capital Stock
—
—
—
0.00
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category